Unapproved Cell/Tissue Product Enforcement Discretion Ends; How Hard Will US FDA Crack Down?
Executive Summary
Entities that already have received letters from the agency raising concerns about marketing unapproved products may not necessarily be the first to face enforcement actions, CBER official says.
You may also be interested in...
Gottlieb: FDA Would Be Subject To More White House Control Under A Second Trump Term
The former commissioner warned that the FDA likely would get very different treatment under a second Trump term than it got under a first. Gottlieb also discussed the need for legislation to help advance ‘n of 1’ drug regulation and how to communicate uncertainty in a wide-ranging interview.
FDA Court Loss Shows ‘Disconnect’ Between Old Regulatory Language And Cell Therapy Technology
That statutory regulatory language never quite keeps up with change in science is an ‘existential crisis,’ former FDA official says. California district court ruling preventing FDA enforcement action against stem cell clinics was ‘a little bit disrespectful to the agency.’
Drugs From Sponsors ‘Located in Russia,’ Would Be Barred From US FDA Review By House Funding Bill
Language of the amendment cleared by appropriators in response to the Russian war against Ukraine in FDA’s fiscal year funding bill is vague, making impact of the funding ban on industry unclear. Democrats supported the amendment but said they wanted to continue to work on language to avoid “unintended consequences.” FDA would get a 10% bump in non-user fee funds under the bill.